Oral rather than intravenous corticosteroids should be used to treat MS relapses -Commentary Jodie M Burton
Despite an expanding arsenal of relapse-preventing medications, acute relapse treatment in multiple sclerosis (MS) remains a common need. Steroids have been used to treat these relapse events for decades. 1 Although there is little debate about the role of steroids in MS relapses (i.e. hastening recovery), there is no standard regarding dose route or regimen, particularly the use of oral over intravenous agents. In this publication, Bowen and Qian argue that there may be evidence intravenous regimens have a greater and faster impact on immune mediators of relapse activity acutely and in the long term, as could be the explanation for the finding in the Optic Neuritis Treatment Trial (ONTT) trial of greater recurrence of optic neuritis in the oral versus intravenous group. 2,3 Le Page and colleagues 4, 5 suggest that newer, well-designed trials of oral versus intravenous corticosteroids, namely, the Corticothrapie Orale dans les Poussees de Sclerose en Plaques (COPOUSEP) trial, provide evidence that efficacy, in the form of relapse recovery, does not differ significantly between routes. The debate is not purely academic, as the estimated direct cost of an MS relapse in North American ranges from US$1066-US$4867 if mild/moderate to >US$11,668-US$12,870 if severe. [6] [7] [8] Even if intravenous corticosteroid therapy is administered at home, the cost is upwards of US$3800. 9 Glucocorticoids are the typical corticosteroid agents of choice, namely, methylprednisolone, which distributes widely in tissues and crosses the blood-brain barrier. 10 Oral methylprednisolone has high bioavailability, but the intravenous form does lead to higher central nervous system (CNS) levels as there is no 'first-pass' effect. 11, 12 While intravenous administration has been the mainstay for years, oral dosing has grown in popularity, with several trials dedicated to determining if the routes differ in clinical efficacy and/or adverse events. One of the earliest blinded, randomized-controlled trials to address this was the ONTT, in which patients with acute optic neuritis were randomized to receive oral prednisone (1 mg/kg/day) for 14 days; intravenous methylprednisolone (250 mg every 6 hours) for 3 days, followed by oral prednisone (1 mg/kg/day) for 11 days; or oral placebo for 14 days. 3 Despite early findings suggesting intravenous methylprednisolone bested oral prednisone in degree of recovery, by 12 months, there was no significant difference between groups. 3 No subsequent study of steroids in MS relapses has replicated the seeming risk of increased relapse activity following oral steroid therapy. 13 Ultimately, the biggest takeaway from the ONTT was that acute steroid therapy in optic neuritis only hastens recovery, and that magnetic resonance imaging (MRI) lesions, not steroid regimen, predicted conversion to clinically definite MS. 13, 14 Trials designed to study glucocorticoids in various MS relapse phenotypes have typically relied upon more bioequivalent dosing over 3-5 days with primary outcomes of recovery (typically in the form of Expanded Disability Status Scale (EDSS)) at 4 weeks.
A Cochrane review of such trials found no significant difference in clinical benefit or significant adverse events between intravenous and oral regimens, albeit the number of methodologically robust trials was limited. 15 The recent multi-centre COPOUSEP trial, designed to address methodological limitations by using an adequate sample size and a non-inferiority design, supports the conclusion of the Cochrane review, that is, a brief oral course (3 days) of either 1000 mg of oral or intravenous methylprednisolone resulted in no evidence of inferiority. 5 Although Bowen and Qian suggest long-term MRI data would address the impact of steroid regimen on future disease activity, the ability to properly monitor and statistically evaluate MRI lesion development over time in such patients would likely be limited given mitigating variables and unavoidable bias. Furthermore, one has to ask whether that is truly the purpose of acute relapse therapy. At least in the first weeks following a relapse, there appears to be no difference in gadolinium or T2 lesion count between oral and intravenous regimens. 16, 17 With respect to adverse events, in the pooled analysis of trials evaluated in the Cochrane review, only dysgeusia was seen significantly more frequently in orally versus intravenoustreated patients, 15 while the COPOUSEP trial showed slightly more cases of insomnia in orally treated patients 5 (also seen in Ramo-Tello et al., 17 but this was no longer significant when pooled in the Cochrane systematic review).
Presently, there is no methodologically compelling evidence of the superiority of intravenous glucocorticoid therapy over a relatively bioequivalent oral regimen with respect to relapse recovery, and minor, somewhat inconsistent differences in adverse event rates. While the question of future disease activity based on relapse regimen remains unanswered, there is little evidence to support the hypothesis. Thus, it would seem that the choice of glucocorticoid route for relapse treatment is best dictated by convenience, cost and resource availability. Relevant comorbidities, such as marked dysphagia or dyspepsia, should also enter into the decision. journals.sagepub.com/home/msj
